Becton Dickinson might have harmed direct purchasers of its syringes by exercising its monopoly power in the syringe market to block less expensive competitors.
Investigation and a pending class action lawsuit on behalf of distributors who bought hypodermic products and syringes directly from Becton Dickinson & Co., alleging that Becton used its monopoly power to exclude less expensive rivals with superior products, and artificially inflated the prices of these important medical devices.
Defendant Details
Name (Stock Symbol)
Brief Description
Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.